NASDAQ:ZYNE Zynerba Pharmaceuticals - ZYNE Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Zynerba Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $0.66 +0.03 (+4.74%) (As of 01/27/2023 12:00 AM ET) Add Compare Share Share Today's Range$0.58▼$0.6850-Day Range$0.50▼$0.6652-Week Range$0.49▼$2.94Volume465,525 shsAverage Volume248,156 shsMarket Capitalization$30.33 millionP/E RatioN/ADividend YieldN/APrice Target$11.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Zynerba Pharmaceuticals MarketRank™ ForecastAnalyst RatingModerate Buy2.67 Rating ScoreUpside/Downside1,559.4% Upside$11.00 Price TargetShort InterestHealthy0.13% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment-0.01Based on 9 Articles This WeekInsider TradingSelling Shares$54,328 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.86) to ($0.68) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.31 out of 5 starsMedical Sector307th out of 1,054 stocksPharmaceutical Preparations Industry143rd out of 517 stocks 3.3 Analyst's Opinion Consensus RatingZynerba Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $11.00, Zynerba Pharmaceuticals has a forecasted upside of 1,559.4% from its current price of $0.66.Amount of Analyst CoverageZynerba Pharmaceuticals has only been the subject of 1 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.13% of the outstanding shares of Zynerba Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverZynerba Pharmaceuticals has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Zynerba Pharmaceuticals has recently decreased by 65.20%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldZynerba Pharmaceuticals does not currently pay a dividend.Dividend GrowthZynerba Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ZYNE. Previous Next 1.7 News and Social Media Coverage News SentimentZynerba Pharmaceuticals has a news sentiment score of -0.01. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.71 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 9 news articles for Zynerba Pharmaceuticals this week, compared to 1 article on an average week.Search Interest12 people have searched for ZYNE on MarketBeat in the last 30 days. This is an increase of 9% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Zynerba Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Zynerba Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $54,328.00 in company stock.Percentage Held by Insiders10.54% of the stock of Zynerba Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 23.82% of the stock of Zynerba Pharmaceuticals is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Zynerba Pharmaceuticals are expected to grow in the coming year, from ($0.86) to ($0.68) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Zynerba Pharmaceuticals is -0.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Zynerba Pharmaceuticals is -0.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioZynerba Pharmaceuticals has a P/B Ratio of 0.39. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Zynerba Pharmaceuticals (NASDAQ:ZYNE) StockZynerba Pharmaceuticals, Inc. engages in the provision of pharmaceutically-produced transdermal cannabinoid therapies. It focuses on the research and development of rare and near-rare neuropsychiatric conditions. The firm offers the Zygel product, which is formulated as a permeation-enhanced gel for transdermal delivery. The company was founded by Audra L. Stinchcomb on January 31, 2007 and is headquartered in Devon, PA.Read More Receive ZYNE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Zynerba Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address ZYNE Stock News HeadlinesJanuary 27, 2023 | marketwatch.comFibromyalgia Treatment Drug Market 2023 : Profiling Key Players, Value Estimation and Analysis by Recent Trends to 2028January 26, 2023 | americanbankingnews.comInsider Selling: Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) Chairman Sells 35,453 Shares of StockJanuary 28, 2023 | Porter & Company (Ad)Is This The End of Capitalism?EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…January 26, 2023 | americanbankingnews.comInsider Selling: Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) CFO Sells 17,769 Shares of StockJanuary 26, 2023 | americanbankingnews.comZynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) President Terri B. Sebree Sells 24,661 SharesJanuary 12, 2023 | msn.comWhat's The Role Of The Endocannabinoid System In Fragile X Syndrome? How Can Cannabidiol Treatment Help? New PaperJanuary 11, 2023 | finance.yahoo.comZynerba Pharmaceuticals Announces Publication in the Journal of Neurodevelopmental Disorders Describing the Role of the Endocannabinoid System and Cannabidiol Therapy in Fragile X SyndromeJanuary 10, 2023 | forbes.comZynerba PharmaceuticalsJanuary 28, 2023 | Porter & Company (Ad)The Next Big Crisis Is HereYou just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.December 21, 2022 | proactiveinvestors.comZynerba Pharmaceuticals revises timeline for release of topline results from Phase 3 RECONNECT trial of Zygel in Fragile X syndromeDecember 21, 2022 | finance.yahoo.comZynerba Pharmaceuticals delays data on genetic disorder drug studyDecember 21, 2022 | finance.yahoo.comZynerba Pharmaceuticals Announces Update on RECONNECT, the Pivotal Phase 3 Trial of Zygel™ in Fragile X SyndromeDecember 21, 2022 | finance.yahoo.comUPDATE 2-Zynerba delays genetic disorder drug data on enrollment challengeDecember 5, 2022 | msn.comCBD-Based Zygel Helps With Anxiety-Related & Behavioral Symptoms In 22q11.2 Deletion Syndrome, Phase 2 Trial RevealsDecember 5, 2022 | finance.yahoo.comZynerba Pharmaceuticals Announces Positive Long-Term Data from Phase 2 INSPIRE Trial in 22q11.2 Deletion Syndrome at the Annual Meeting of the American College of NeuropsychopharmacologyNovember 29, 2022 | finance.yahoo.comZynerba Pharmaceuticals Announces Poster Presentation at the Annual Meeting of the American College of NeuropsychopharmacologyNovember 28, 2022 | proactiveinvestors.comZynerba Pharmaceuticals' Zygel shows meaningful behavioral symptom treatment progress in Fragile X patients in phase 3 trialNovember 28, 2022 | finance.yahoo.comZynerba Pharmaceuticals Announces Publication of Data from Phase 3 CONNECT-FX Study of Zygel™ in the Journal of Neurodevelopmental DisordersNovember 15, 2022 | proactiveinvestors.comZynerba Pharmaceuticals granted orphan drug designation by EC for Zygel active ingredient to treat 22qNovember 15, 2022 | finance.yahoo.comZynerba Pharmaceuticals Announces European Commission Has Granted Orphan Drug Designation for Zygel™ in 22q11.2 Deletion SyndromeNovember 14, 2022 | msn.comZynerba Pharmaceuticals R&D Expenses For Q3 Reach $5M, Here Are The DetailsNovember 14, 2022 | proactiveinvestors.comZynerba ends 3Q with robust $55.9M cash runway to advance its Zygel CBD Gel for Fragile X SyndromeNovember 14, 2022 | finance.yahoo.comZynerba Pharmaceuticals Reports Third Quarter 2022 Financial Results and Operational HighlightsNovember 3, 2022 | proactiveinvestors.comZynerba Pharmaceuticals boosts intellectual property portfolio with new patents for ZygelNovember 2, 2022 | proactiveinvestors.comZynerba Pharmaceuticals gets another US Patent for its transdermal cannabidiol product candidate, ZygelNovember 2, 2022 | proactiveinvestors.comZynerba Pharmaceuticals gets another US Patent for its transdermal cannabidiol product, ZygelNovember 2, 2022 | finance.yahoo.comZynerba Pharmaceuticals Announces Issuance of New U.S. Patent for Zygel™ for the Treatment of 22q11.2 Deletion SyndromeSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive ZYNE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Zynerba Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address ZYNE Company Calendar Last Earnings11/14/2022Today1/28/2023Next Earnings (Estimated)3/07/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ZYNE CUSIPN/A CIK1621443 Webwww.zynerba.com Phone(484) 581-7505FaxN/AEmployees28Year FoundedN/APrice Target and Rating Average Stock Price Forecast$11.00 High Stock Price Forecast$11.00 Low Stock Price Forecast$11.00 Forecasted Upside/Downside+1,559.4%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.87) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-37,310,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-58.25% Return on Assets-50.31% Debt Debt-to-Equity RatioN/A Current Ratio6.45 Quick Ratio6.45 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.72 per share Price / Book0.39Miscellaneous Outstanding Shares45,750,000Free Float40,931,000Market Cap$30.33 million OptionableOptionable Beta1.64 Key ExecutivesArmando AnidoChairman & Chief Executive OfficerTerri B. SebreePresidentJames E. FickenscherChief Financial Officer & VP-Corporate DevelopmentNancy TichVice President-ClinicalCarol B. O'NeillVice President-DevelopmentKey CompetitorsComera Life SciencesNASDAQ:CMRAGelesisNYSE:GLSAptinyxNASDAQ:APTXAthenexNASDAQ:ATNXKala PharmaceuticalsNASDAQ:KALAView All CompetitorsInsiders & InstitutionsArmando AnidoSold 35,453 sharesTotal: $21,271.80 ($0.60/share)Terri B SebreeSold 24,661 sharesTotal: $14,796.60 ($0.60/share)James E FickenscherSold 17,769 sharesTotal: $10,661.40 ($0.60/share)Brian RosenbergerSold 12,663 sharesTotal: $7,597.80 ($0.60/share)Jane Street Group LLCBought 63,215 shares on 11/16/2022Ownership: 0.138%View All Insider TransactionsView All Institutional Transactions ZYNE Stock - Frequently Asked Questions Should I buy or sell Zynerba Pharmaceuticals stock right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zynerba Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ZYNE shares. View ZYNE analyst ratings or view top-rated stocks. What is Zynerba Pharmaceuticals' stock price forecast for 2023? 3 Wall Street analysts have issued 12-month target prices for Zynerba Pharmaceuticals' stock. Their ZYNE share price forecasts range from $11.00 to $11.00. On average, they expect the company's share price to reach $11.00 in the next year. This suggests a possible upside of 1,559.4% from the stock's current price. View analysts price targets for ZYNE or view top-rated stocks among Wall Street analysts. How have ZYNE shares performed in 2023? Zynerba Pharmaceuticals' stock was trading at $0.53 at the beginning of the year. Since then, ZYNE stock has increased by 25.1% and is now trading at $0.6629. View the best growth stocks for 2023 here. When is Zynerba Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 7th 2023. View our ZYNE earnings forecast. How were Zynerba Pharmaceuticals' earnings last quarter? Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) released its quarterly earnings data on Monday, November, 14th. The company reported ($0.20) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.21) by $0.01. What other stocks do shareholders of Zynerba Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Zynerba Pharmaceuticals investors own include Cara Therapeutics (CARA), GW Pharmaceuticals (GWPH), Cronos Group (CRON), Aurora Cannabis (ACB), NVIDIA (NVDA), Advanced Micro Devices (AMD), Alibaba Group (BABA), Shopify (SHOP) and Micron Technology (MU). When did Zynerba Pharmaceuticals IPO? (ZYNE) raised $42 million in an IPO on Wednesday, August 5th 2015. The company issued 3,000,000 shares at a price of $13.00-$15.00 per share. Jefferies and Piper Jaffray served as the underwriters for the IPO and Canaccord Genuity and Oppenheimer & Co. were co-managers. What is Zynerba Pharmaceuticals' stock symbol? Zynerba Pharmaceuticals trades on the NASDAQ under the ticker symbol "ZYNE." How do I buy shares of Zynerba Pharmaceuticals? Shares of ZYNE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Zynerba Pharmaceuticals' stock price today? One share of ZYNE stock can currently be purchased for approximately $0.66. How much money does Zynerba Pharmaceuticals make? Zynerba Pharmaceuticals (NASDAQ:ZYNE) has a market capitalization of $30.33 million. The company earns $-37,310,000.00 in net income (profit) each year or ($0.87) on an earnings per share basis. How can I contact Zynerba Pharmaceuticals? Zynerba Pharmaceuticals' mailing address is 80 W. LANCASTER AVENUE SUITE 300, DEVON PA, 19333. The official website for the company is www.zynerba.com. The company can be reached via phone at (484) 581-7505 or via email at investorrelations@zynerba.com. This page (NASDAQ:ZYNE) was last updated on 1/28/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.